Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis

Inclusion Criteria: 1. Participant is ≥18 years of age; 2. Participant has a confirmed diagnosis of PsA per the 2006 Classification criteria for Psoriatic Arthritis (CASPAR) with symptoms for ≥6 months prior to the Screening Visit; 3. Participant has active disease (defined by a TJC68 of ≥3 and a SJC66 of ≥3); 4. Participant has either current active PsO or a dermatologist confirmed history of PsO; 5. Participant tests negative for rheumatoid factor (RF) at the Screening Visit; 6. Participant tests negative for anti-cyclic citrullinated peptide (CCP) antibodies at the Screening Visit; 7. Participant must be, in the opinion of the investigator, a suitable candidate for treatment with adalimumab per approved local product information. Exclusion Criteria: 1. Participant with known hypersensitivity to sonelokimab or any of its excipients; 2. Participant with known hypersensitivity to adalimumab or any of its excipients; 3. Participant who has previously failed on anti-interleukin (IL)-17 therapy; 4. Participant who has previously failed on anti-tumor necrosis factor alpha (TNFα) therapy; 5. Participant who has had previous exposure to more than 2 biologic agents of any type to treat PsA prior to the Screening Visit; 6. Participant who has a diagnosis of chronic inflammatory conditions other than PsO or PsA; 7. Participant who has a diagnosis of arthritis mutilans